Carregant...
Clinical PARP inhibitors do not abrogate PARP1 exchange at DNA damage sites in vivo
DNA breaks recruit and activate PARP1/2, which deposit poly-ADP-ribose (PAR) to recruit XRCC1-Ligase3 and other repair factors to promote DNA repair. Clinical PARP inhibitors (PARPi) extend the lifetime of damage-induced PARP1/2 foci, referred to as ‘trapping’. To understand the molecular nature of...
Guardat en:
| Publicat a: | Nucleic Acids Res |
|---|---|
| Autors principals: | , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Oxford University Press
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7515702/ https://ncbi.nlm.nih.gov/pubmed/32890402 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/nar/gkaa718 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|